Antiemetic extended release solid dosage forms

A solid oral dosage form comprising:

• a core comprising hypromellose, 18 mg of ondansetron or an equivalent amount of an ondansetron salt thereof, and sodium citrate anhydrous;
• a first seal coat surrounding the core and comprising hypromellose;
• and
• an immediate release drug layer surrounding the first seal coat and comprising hypromellose and 6 mg of ondansetron or an equivalent amount of an ondansetron salt thereof, the immediate release drug layer sufficient to release the ondansetron over a period of at least 1 hour,
• wherein the total amount of ondansetron in the dosage form is released over 24 hours.

A solid oral dosage form comprising:

• a core comprising a non-ionic polymer matrix, a first amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed within the matrix, and a salt dispersed within the matrix;
• a first seal coat surrounding the core, wherein the first seal coat is comprised of a non-ionic polymer matrix;
• and an immediate release drug layer surrounding the first seal coat, wherein the immediate release drug layer comprises a non-ionic polymer and a second amount of ondansetron or an equivalent amount of an ondansetron salt thereof dispersed therein, wherein the solid oral dosage form results in an in vitro ondansetron dissolution profile when measured in a type 2 paddle dissolution apparatus at 37° C. in aqueous solution containing distilled water at 50 rpm that exhibits:
• a) from about 20% to 50% of the total ondansetron is released after two and a half hours of measurement in the apparatus;
• b) from about 50% to 70% of the total ondansetron is released after five hours of measurement in the apparatus;
• and c) no less than about 90% of the total ondansetron is released after fifteen hours of measurement in the apparatus.